A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers.

Trial Profile

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Avibactam/ceftaroline fosamil (Primary) ; Avibactam/ceftazidime (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Jun 2016 According to AstraZeneca media release, the European Commission has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.
    • 03 Apr 2012 Primary endpoint 'QT-interval' has been met.
    • 03 Apr 2012 Results presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top